Caxton Associates (New York)’s Lexicon Pharmaceuticals LXRX Stock Holding History

Caxton Associates (New York)’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-46,281	Closed	-$88.4K	–	577
2022 Q4	$88.4K	Sell	46,281 -8,500	-16%	-$18.1K	0.01%	425
2022 Q3	$131K	Buy	+54,781	New	+$152K	0.02%	433
2021 Q2	–	Sell	-28,705	Closed	-$168K	–	547
2021 Q1	$168K	Buy	28,705 +17,958	+167%	+$124K	0.02%	383
2020 Q4	$37K	Buy	+10,747	New	+$20.5K	﹤0.01%	137

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caxton Associates (New York)'s LXRX Position: Q1 2023 in Review

Caxton Associates (New York) sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2023, closing a stake of 46,281 shares — an estimated $88.4K sold.

Caxton Associates (New York) first reported a position in LXRX in Q4 2020 and held it in 4 quarters. The position peaked at $168K in Q1 2021. 104 funds tracked by Wall St. Rank hold LXRX as of Q1 2023.

Caxton Associates (New York) reported no remaining Lexicon Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Caxton Associates (New York) sold 46,281 Lexicon Pharmaceuticals shares in Q1 2023, an estimated $88.4K.
Caxton Associates (New York) first reported a position in Lexicon Pharmaceuticals in Q4 2020 and held it in 4 quarters.
Caxton Associates (New York)'s Lexicon Pharmaceuticals position peaked at $168K in Q1 2021.
104 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.